maplirpacept

Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPα) linked to the Fc region of human immunoglobulin IgG4. It acts as a decoy receptor that selectively targets and binds to CD47 antigen expressed on tumor cells, blocking the interaction between CD47 and endogenous SIRPα. This blockade disrupts the "don't eat me" signal used by cancer cells to evade phagocytosis, thereby promoting macrophage-mediated phagocytosis and destruction of tumor cells. Maplirpacept is designed with minimal binding to red blood cells, potentially reducing the risk for hemolytic anemia compared to other anti-CD47 therapies. The drug is administered intravenously and is being developed primarily for hematological malignancies such as primary mediastinal B-cell lymphoma, multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, follicular lymphoma, classic Hodgkin’s lymphoma, indolent non-Hodgkin’s lymphoma, and solid tumors[1][2][3][4][6][8].

Other names

SIRPA-IGG4-FC FUSION PROTEIN TTI-622SIRPA-IGG-4-FC FUSION PROTEIN TTI-622SIRPA-IGG 4-FC FUSION PROTEIN TTI-622